The U.S. Food and Drug Administration has declined Humanigen Inc's (HGEN.O) request for emergency use authorization (EUA) of its lenzilumab drug to treat newly hospitalized COVID-19 patients, as stated by the company on Thursday. "In its letter, FDA stated that it was unable to conclude that the known